| Assay ID | Title | Year | Journal | Article |
|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID699937 | Selectivity ratio of Ki for human D2L receptor to Ki for human D3 receptor | 2012 | Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
| Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. |
| AID1157839 | Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
| Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor. |
| AID731812 | Agonist activity at human muscarinic M1 receptor expressed in CHO cells assessed as stimulation of ERK1/2 phosphorylation after 15 mins by Alphascreen Surefire assay | 2013 | Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
| Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. |
| AID699938 | Displacement of [125I]IABN from human D3 receptor expressed in HEK293 cells after 60 mins by gamma counting analysis | 2012 | Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
| Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. |
| AID699929 | Partial agonist activity at human D3 receptor expressed in HEK293T cells coexpressing GalphaoA-91-Rluc8 and mVenus-Gbeta1gamma2 after 2 mins by bioluminescence resonance energy transfer assay relative to dopamine | 2012 | Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
| Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. |
| AID731815 | Displacement of [3H]-NMS from recombinant muscarinic M2 receptor (unknown origin) expressed in CHOK1 cells after 60 mins by liquid scintillation counting analysis | 2013 | Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
| Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. |
| AID731813 | Displacement of [3H]-NMS from recombinant muscarinic M4 receptor (unknown origin) expressed in CHOK1 cells after 60 mins by liquid scintillation counting analysis | 2013 | Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
| Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. |
| AID731814 | Displacement of [3H]-NMS from recombinant muscarinic M3 receptor (unknown origin) expressed in CHOK1 cells after 60 mins by liquid scintillation counting analysis | 2013 | Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
| Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. |
| AID731816 | Displacement of [3H]-NMS from recombinant muscarinic M1 receptor (unknown origin) expressed in CHOK1 cells after 60 mins by liquid scintillation counting analysis | 2013 | Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
| Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. |
| AID731810 | Agonist activity at human muscarinic M3 receptor expressed in CHO cells assessed as stimulation of ERK1/2 phosphorylation after 15 mins by Alphascreen Surefire assay | 2013 | Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
| Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. |
| AID731811 | Agonist activity at human muscarinic M2 receptor expressed in CHO cells assessed as stimulation of ERK1/2 phosphorylation after 15 mins by Alphascreen Surefire assay | 2013 | Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
| Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. |
| AID731809 | Agonist activity at human muscarinic M4 receptor expressed in CHO cells assessed as stimulation of ERK1/2 phosphorylation after 15 mins by Alphascreen Surefire assay | 2013 | Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
| Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. |
| AID731817 | Displacement of [3H]dihydroalprenolol from human wild type beta1 adrenergic receptor expressed in HEK293 cell membranes after 90 mins by liquid scintillation counting analysis | 2013 | Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
| Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. |
| AID699930 | Partial agonist activity at human D2S receptor expressed in HEK293T cells coexpressing GalphaoA-91-Rluc8 and mVenus-Gbeta1gamma2 after 2 mins by bioluminescence resonance energy transfer assay relative to dopamine | 2012 | Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
| Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. |
| AID699939 | Displacement of [125I]IABN from human D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis | 2012 | Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
| Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. |
| AID697988 | Partial agonist activity at D3 receptor relative to control | 2012 | Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
| A straightforward approach for engineering efficacy and selectivity at GPCRs. |
| AID697989 | Partial agonist activity at D2 receptor relative to control | 2012 | Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
| A straightforward approach for engineering efficacy and selectivity at GPCRs. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |